InMed Pharmaceuticals Increases Cannabinoid Yield to 5 g/L with IntegraSyn™ in Advance of Commercial Scale Production 5 g/L cannabinoid yield significantly exceeds reported industry yieldsSignificantly reduces the overall cost of rare cannabinoid manufacturingContinued advancement to GMP-ready large-scale batch...

InMed Pharmaceuticals Announces Voluntary Delisting from TSX VANCOUVER, British Columbia, April 27, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq:INM) (TSX:IN), a clinical-stage company developing cannabinoid-based...